answer text |
<p>Decisions on the prescribing of medicines are a matter for clinicians in discussion
with their patients.</p><p> </p><p>National Health Service commissioners are legally
required by regulations to fund those anticoagulant treatments recommended by the
National Institute for Health and Care Excellence(NICE) in its technology appraisal
guidance.</p><p> </p><p>The NICE Implementation Collaborative published a consensus
statement on supporting the use of novel oral anticoagulants in non-valvular atrial
fibrillation on 18 June 2014. This is available at:</p><p> </p><p>www.nice.org.uk/resource/CG180/pdf/c/cg180-atrial-fibrillation-nic-consensus-statement-on-the-use-of-noacs?id=gvyb3hjdqrcjtn6ytpwx3ydb64</p><p>
</p><p>NICE published its updated clinical guideline on the management of atrial fibrillation
on 25 June 2014 which recommends that novel oral anticoagulants should be offered
where appropriate.</p><p> </p><p>The latest data from the Innovation Scorecard show
that uptake of new anticoagulants across England is increasing. Further information
is available at:</p><p> </p><p>www.hscic.gov.uk/catalogue/PUB13669</p><p> </p>
|
|